At two years, Gilead lymphoma therapy active in 40 percent of patients
SAN DIEGO (Reuters) – Nearly 40 percent of lymphoma patients treated with a single infusion of Gilead Sciences Inc’s Yescarta continued to respond to the cell therapy after at least two years of follow up, the company said on Sunday. FILE PHOTO: A Gilead Sciences, Inc. office is shown in Foster City, California, U.S. May… Read More »